Pharmacodynamics change and drug resistance of hypernormal dose fluoroquinolone in the treatment of patients with respiratory tract infection
10.7619/jcmp.201805003
- VernacularTitle:氟喹诺酮超常规剂量治疗呼吸道感染的药效学变化和耐药状况
- Author:
Jiefei WEI
1
Author Information
1. 河南省南阳市第二人民医院呼吸内科
- Keywords:
fluoroquinolone;
respiratory tract infection;
pharmacodynamics;
drug resistance;
hypernormal dose
- From:
Journal of Clinical Medicine in Practice
2018;22(5):9-12
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the pharmacodynamics change and drug resistance of hypernormal dose fluoroquinolone in the treatment of patients with respiratory tract infection.Methods Clinical data of 120 patients with respiratory tract infection was analyzed retrospectively,and they were divided into hypernormal group (study group) and routine group (control group) according to fluoroquinolones dose.Pharmacodynamic change and drug resistance were analyzed between two groups.Results There were no significant differences in age,sex,weight and treatment time between the two groups (P ＞ 0.05),but the treatment cost in the study group was significantly higher than the control group (P ＜ 0.01).The maximum plasma concentrations (Cmax) of levofloxacin,moxifloxacin and ciprofloxacin were significantly higher than the control group,the peak time (Tmax) was significantly lower than the control group (P ＜ 0.05).Drug half-life (T1/2) showed no significant difference between two groups (P ＞ 0.05).The overall effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05),and ratio of drug resistance was significantly higher than the control group (P ＜ 0.05).Conclusion Application of hypernormal dose fluoroquinolone is effective in treatment of patients with respiratory tract infection,but its drug resistance is higher,so the clinical dosage should be reasonable controlled.
